BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8634146)

  • 21. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1).
    Adachi Y; Matsubara S; Pedraza C; Ozawa M; Tsutsui J; Takamatsu H; Noguchi H; Akiyama T; Muramatsu T
    Oncogene; 1996 Nov; 13(10):2197-203. PubMed ID: 8950987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.
    Maheswaran S; Englert C; Bennett P; Heinrich G; Haber DA
    Genes Dev; 1995 Sep; 9(17):2143-56. PubMed ID: 7657166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites.
    Lee S; Park U; Lee YI
    Virology; 2001 May; 283(2):167-77. PubMed ID: 11336542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional properties of WT1.
    Haber DA; Englert C; Maheswaran S
    Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.
    Mayo MW; Wang CY; Drouin SS; Madrid LV; Marshall AF; Reed JC; Weissman BE; Baldwin AS
    EMBO J; 1999 Jul; 18(14):3990-4003. PubMed ID: 10406804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of nov by WT1: a potential role for nov in nephrogenesis.
    Martinerie C; Chevalier G; Rauscher FJ; Perbal B
    Oncogene; 1996 Apr; 12(7):1479-92. PubMed ID: 8622864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1).
    Dehbi M; Ghahremani M; Lechner M; Dressler G; Pelletier J
    Oncogene; 1996 Aug; 13(3):447-53. PubMed ID: 8760285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells.
    Damon SE; Plymate SR; Carroll JM; Sprenger CC; Dechsukhum C; Ware JL; Roberts CT
    Endocrinology; 2001 Jan; 142(1):21-7. PubMed ID: 11145562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors.
    Liu J; Nau MM; Yeh JC; Allegra CJ; Chu E; Wright JJ
    Clin Cancer Res; 2000 Sep; 6(9):3522-9. PubMed ID: 10999739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1.
    Kim JM; Hong Y; Semba K; Kim S
    Biochem Biophys Res Commun; 2000 Jan; 267(1):59-63. PubMed ID: 10623574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.
    Sakamoto Y; Yoshida M; Semba K; Hunter T
    Oncogene; 1997 Oct; 15(17):2001-12. PubMed ID: 9366517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ expression of the early growth response gene-1 during murine nephrogenesis.
    Rackley RR; Kessler PM; Campbell C; Williams BR
    J Urol; 1995 Aug; 154(2 Pt 2):700-5. PubMed ID: 7609158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
    Gashler AL; Bonthron DT; Madden SL; Rauscher FJ; Collins T; Sukhatme VP
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10984-8. PubMed ID: 1332065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel replication inhibitory function of the developmental regulator/transcription repressor protein WT1 encoded by the Wilms' tumor gene.
    Anant S; Axenovich SA; Madden SL; Rauscher FJ; Subramanian KN
    Oncogene; 1994 Nov; 9(11):3113-26. PubMed ID: 7936634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1.
    Goodyer P; Dehbi M; Torban E; Bruening W; Pelletier J
    Oncogene; 1995 Mar; 10(6):1125-9. PubMed ID: 7700638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The WT1 Wilms' tumor suppressor gene is a downstream target for insulin-like growth factor-I (IGF-I) action in PC12 cells.
    Sarfstein R; Werner H
    J Neurochem; 2006 Nov; 99(3):818-26. PubMed ID: 16911581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional regulation of the AP-2alpha promoter by BTEB-1 and AP-2rep, a novel wt-1/egr-related zinc finger repressor.
    Imhof A; Schuierer M; Werner O; Moser M; Roth C; Bauer R; Buettner R
    Mol Cell Biol; 1999 Jan; 19(1):194-204. PubMed ID: 9858544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
    Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
    Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.